Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis by Robert Morlock et al.
ORIGINAL RESEARCH
Disease Control, Health Resource Use, Healthcare
Costs, and Predictors in Gout Patients in the United
States, the United Kingdom, Germany, and France:
A Retrospective Analysis
Robert Morlock . Pierre Chevalier . Laura Horne . Javier Nuevo .
Chris Storgard . Lalitha Aiyer . Dionne M. Hines . Xavier Ansolabehere .
Fredrik Nyberg
Received: March 15, 2016 / Published online: May 25, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: The present study aimed to assess
disease control, health resource utilization
(HRU), and healthcare costs, and their
predictors in gout patients across the USA, UK,
Germany, and France.
Methods: Data were extracted from the
PharMetrics Plus (USA), Clinical Practice
Research Datalink–Hospital Episode Statistics
(UK), and Disease Analyzer databases
(Germany and France) for adult gout patients
over a 3-year period: 2009–2011 (all dates
?1 year for France). Patients had ‘‘prevalent
established gout’’ (i.e., were treated with
urate-lowering therapy [ULT] or eligible for
ULT based on American College of
Rheumatology guidelines) in the preindex
panel-year, with January 1 of the second study
year as the study index date. Assessments of
disease control (uncontrolled gout definition:
C1 serum urate (sUA) elevation or C2 flares;
analysis limited to the subpopulation with sUA)
data, HRU, and costs were in the second
post-index panel-year, while potential
predictors (demographics and gout treatment
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characteristics) were identified in the first
post-index panel-year.
Results: Treatment rates were high ([70% with
chronic urate-lowering treatment in all
countries but France), while between 31.3%
(France) and 62.9% (USA) of patients remained
uncontrolled. Predictors of control included
female gender and high adherence. In
Germany, the UK, and France, lack of disease
control predicted increased gout-attributed
costs and increased HRU, both gout-attributed
(also in the USA) and non-gout-attributed.
Conclusion: Gout management remains
suboptimal, as many patients remain
uncontrolled despite using urate-lowering
treatment. Effective and convenient treatment
options are needed to improve disease control
and minimize additional HRU and costs.
Funding: AstraZeneca.
Keywords: Gout; Healthcare costs, Health
resource utilization; Urate-lowering therapy
INTRODUCTION
Uncontrolled gout is a debilitating medical
condition resulting from monosodium urate
(MSU) crystal deposition throughout the body,
manifesting as recurrent attacks of acute
inflammatory arthritis of the peripheral joints.
Gout affects about 1–4% of the population in
Western developed countries, and is more
prevalent in men [1–3]. The hallmark precursor
to gout is hyperuricemia, defined as serum urate
(sUA) levels [6.8 mg/dl (&400 lmol/l); this
predominantly results from inefficient renal
uric acid excretion, rather than overproduction
[4, 5]. Clinical diagnosis of gout is confirmed by
the presence of characteristic MSU crystals in the
joint fluid [2, 6]. While there is evidence of
familial clustering in gout, risk factors include
cardiovascular/metabolic diseases (e.g., obesity,
arterial hypertension, diabetes,
hypercholesterolemia, and renal failure) and
menopause, as well as diets rich in purines,
alcohol consumption, and thiazide diuretic use
[4].
Management of gout encompasses both
short-term control of acute attacks and
long-term treatment to reduce sUA, thereby
dissolving MSU crystals and preventing further
acute manifestation of flares [4]. Treatment of
acute attacks involves use of colchicine,
nonsteroidal anti-inflammatory drugs (NSAID),
or corticosteroids [7, 8]. At the first flare, dietary
and lifestyle modifications are advised to prevent
recurrence. For long-term management of gout,
European League Against Rheumatism (EULAR)
and American College of Rheumatology (ACR)
treatment guidelines recommend urate-lowering
therapies (ULTs) to decrease sUA to \6 mg/dl,
while target levels \5 mg/dl are recommended
for patients with recurrent acute attacks, tophi, or
radiographic gout changes [7, 8]. British Society
of Rheumatology guidelines recommend target
sUA \5 mg/dl [9]. All guidelines recommend
xanthine oxidase inhibitors (e.g., allopurinol,
febuxostat), which inhibit uric acid production,
as first-line therapy. When xanthine oxidase
inhibitors are contraindicated or fail to achieve
sUA targets, the addition or use of a uricosuric
agent (e.g., probenecid, benzbromarone), which
increases renal excretion of uric acid, is
recommended [8]. Unfortunately, there is
widespread evidence that patients with gout are
not treated according to these guidelines and
therefore their gout remains poorly controlled
[10–13].
Gout progression can cause permanent joint
destruction, bone erosion, and organ damage if
hyperuricemia is left uncontrolled [14]. In
addition to causing pain, disability, and
diminished quality of life, poorly controlled
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gout is associated with significantly higher
healthcare costs and loss in productivity
[15–17]. In a US prospective study, patients
with frequent gout attacks had a higher
prevalence of comorbidities (chronic kidney
disease, hypertension, dyslipidemia, ischemic
heart disease, heart failure, and arthritis) than
those with infrequent attacks [18]. They also
had higher mean numbers of all-cause and
gout-attributed outpatient and emergency
department visits, as well as substantially
greater healthcare costs than those with
infrequent attacks [18]. Another study found
higher outpatient, emergency, and inpatient
services utilization among patients with gout
than matched non-gout patients [19]; all-cause
healthcare costs were also higher for gout
patients, and increased with increasing sUA.
Overall, however, data on the health and cost
burden associated with gout are scarce.
Moreover, significant proportions of patients
continue to experience elevated sUA, recurrent
flares, and tophi despite ULT [20, 21].
By analyzing data extracted from electronic
medical record (EMR) and administrative claims
databases, our study sought to investigate large
populations of gout patients in the USA, UK,
Germany, and France. Our objectives were: to
assess the rate of uncontrolled gout and identify
predictors of disease control (including ULT
characteristics) in these populations; to
estimate health resource utilization (HRU) and
healthcare costs in that patient group; and to
identify predictors of HRU and healthcare costs.
METHODS
Data Sources
This study investigated gout patients in the
USA, UK, Germany, and France using
retrospective healthcare data extracted from
EMR and administrative claims databases: US
IMS PharMetrics Plus database [22–24]; UK
Clinical Practice Research Database (CPRD)
and Hospital Episode Statistics database [25,
26]; and IMS Disease Analyzers in Germany [27,
28] and France [29, 30], respectively. Details on
these databases are in supplemental Table S1.
Study Design
This was an observational cohort study of
established gout patients in four countries. For
the USA, UK, and Germany, the study period
ran from January 1, 2009 to December 31, 2011.
All study objectives were assessed through a
longitudinal panel design, where the study
period was divided into fixed time periods of 1
calendar year (i.e., panel-years) (Fig. 1). This
design was employed due to the dependence of
analysis on various time-varying constructs
(e.g., disease control, resource use, or
cumulated costs) requiring measurement over
defined time periods. The index-date was
January 1, 2010. The 12-month period
immediately preceding the index-date was
defined as the preindex panel-year and was
used to identify eligible patients and determine
baseline characteristics. Treatment
characteristics and predictors of the main
outcomes (disease control status, HRU, costs)
were assessed in the first post-index panel-year
(full year 2010), while outcomes were assessed
in the second post-index panel-year (full year
2011). For France, the same procedures were
used, but the timeline was moved forward by
1 year to synchronize the study window with
information collected through an observational
study (only available for 2012), which was
conducted in a subset of general practitioners/
primary care physicians (GPs/PCPs) and
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included additional information on
hospitalizations and laboratory results.
Patient Selection
In all four countries, the study population
consisted of adult patients (C18 years at
index-date) identified with established gout—
i.e., receiving ULT or eligible for ULT according
to ACR guidelines [8]—during the course of the
preindex panel-year. ACR criteria were based
on: a documented diagnosis code for gout or a
prescription for colchicine or a colchicine
combination; and a diagnostic code for
moderate chronic kidney disease, urolithiasis,
or tophus or the occurrence of two gout flares.
Tophus coding was based on the International
Classification of Diseases (ICD)-9 for US data;
ICD-10 for German, French and UK hospital
data; and Read codes for UK primary care data.
Eligible patients were additionally required to
be present in the database during the full 3-year
period covered by the study. Patients with
hematologic cancer, severe renal impairment
(per diagnoses or laboratory values [estimated
creatinine clearance \30 ml/min]), tumor lysis
syndrome, or Lesch–Nyhan syndrome
documented preindex were excluded.
For all analyses involving disease control
status, the analysis population was limited to
those with C1 sUA measurement during the
period of assessment of control status.
Definition of Disease Control Status
Among those with C1 sUA measurement
during the period of assessment of control
status, a defined control status over the course
of a panel-year was determined as follows: gout
was considered controlled if no sUA elevation
([6 mg/dl), no diagnosis code for tophus, or no
flare was documented, and as uncontrolled
if C2 flares or a sUA elevation was reported.
Control status was assessed in the second
post-index panel-year and its predictors
were identified in the first post-index
panel-year; control status was also assessed in
the first post-index panel-year as a potential
predictor in different multivariate models.
Remaining cases (e.g., one flare without sUA
elevation) were labeled as ‘‘undefined control
status’’. Gout flare occurrence was defined by
an office visit or hospitalization with a
diagnosis of gout, followed by prescription of
NSAID, colchicine, oral corticosteroid, or
interleukin-1 antagonist within 3 days; or by
an office visit or hospitalization with a
diagnosis of joint pain, followed by
prescription of colchicine within 3 days [31,
32].
Fig. 1 Study design. HRU health resource utilization
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Definition of Treatment Characteristics
Medications of interest in the context of this
study were ULTs—xanthine oxidase inhibitors
(allopurinol, febuxostat, or any combination
including allopurinol or febuxostat), uric acid
metabolism catalysts (pegloticase), and
uricosuric agents (probenecid or
sulfinpyrazone).
• Patients were considered ‘‘chronic
ULT-treated’’ if they had been continuously
exposed to ULT for C60 consecutive days
over the panel-year, regardless of the number
of prescriptions or type of ULT.
Discontinuation was defined as a gap of
[50% of the days’ supply of the last
prescription (starting from the end date of
the supply in the last prescription).
• Patients prescribed a ULT during the course
of the panel-year but who did not qualify as
chronic ULT-treated were categorized as
patients ‘‘with less than 60 consecutive
days’ supply of ULT’’ and reported as a
distinct category.
• Patients without a prescription for a ULT
during the panel-year were categorized as
‘‘untreated patients’’.
Persistence with ULT within each panel was
defined as the number of consecutive days on
any ULT, from treatment initiation until the
first observed defined gap in days’ supply during
the follow-up period (discontinuation) or the
end of the panel, whichever occurred first.
Adherence to ULT was calculated as
persistence divided by the number of days in
the panel (i.e., 365).
Identification of HRU
All healthcare resources utilized over the course
of the second post-index panel-year were
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GP/PCP consultations N patients (%) 61,809 (58.8) 29,518 (99.2) 48,684 (97.9) 12,739 (96.4)
N visits/patient
(mean [SD])
4.1 (5.8) 45.7 (35.4)b 4.7 (4.1) 6.4 (4.2)
Specialist ofﬁce visit N patients (%) 82,419 (78.4) 5982 (20.1) 31,562 (63.5) NA
N visits/patient
(mean [SD])
10.3 (17.3) 1.4 (0.7) 3.7 (2.9) NA
Laboratory and pathology
services
N patients (%) 82,410 (78.4) 29,687 (99.8) 49,722 (100.0) 2593 (19.6)
N visits/patient
(mean [SD])
14.5 (19.4) 7.1 (6.9) 6.6 (7.5) 2.6 (2.6)
ED visits N patients (%) 18,320 (17.4) 2145 (7.2) NA NA
N visits/patient
(mean [SD])
1.6 (1.6) 1.7 (1.3) NA NA
Hospitalizations N patients (%) 10,507 (10.0) 4879 (27.2c) 6258 (12.6) 97 (10.3d)
N visits/patient
(mean [SD])
1.5 (1.1) 2.6 (8.5) 1.5 (1.2) 1.2 (0.7)
Gout-related
GP/PCP consultations N patients (%) 29,598 (28.2) 2330 (7.8) 226 (0.5) 923 (7.0)
N visits/patient
(mean [SD])
2.0 (2.4) 1.5 (1.1) 1.5 (1.0) 2.0 (1.8)
Specialist ofﬁce visit N patients (%) 32,831 (31.2) 1372 (4.6) NA NA
N visits/patient
(mean [SD])
4.2 (10.8) 1.1 (0.3) NA NA
Laboratory and pathology
services
N patients (%) 38,087 (36.2) 4421 (14.9) 20,937 (42.1) 964 (7.3)
N visits/patient
(mean [SD])
7.4 (8.5) 1.2 (0.7) 1.9 (1.5) 1.3 (0.6)
ED visits N patients (%) 5512 (5.2) 56 (0.2) NA NA
N visits/patient
(mean [SD])
1.3 (0.8) 1.1 (0.5) NA NA
Hospitalizations N patients (%) 1862 (1.8) 105 (0.4b) 13 (\0.1) 37 (3.9d)
N visits/patient
(mean [SD])
1.1 (0.3) 1.2 (0.5) 1.2 (0.6) 1.1 (0.3)
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and non-gout-attributed HRU. All visits or
hospitalizations associated with a diagnosis of
gout or joint pain were attributed to gout.
Gout-attributed laboratory services included all
sUA tests. Gout-attributed pharmacy services
included all prescriptions for gout-related
medications (i.e., ULT, anti-inflammatories,
and colchicine). Non-gout-attributed
utilization included all other outpatient,
inpatient, and pharmacy services.
Country-specific limitations inherent to
databases hindered collection of exactly the
same information in all four countries; details
are available in supplemental Table S1.
Valorization of HRU
For the USA, healthcare costs/charges associated
with utilization were determined by the allowed
amount (the amount the health plan allows for
a particular service, including the paid amount
plus any member liability), as documented in
the PharMetrics data. For the remaining
countries, costs were not available directly
from databases, but were calculated by
multiplying the number of units retrieved in
the database by unit costs from published
sources. Cost calculation for France was
restricted to the subset of patients with
complementary data on hospitalizations
(n = 943). All costs were converted into 2011
United States dollars (USD) using historical
‘‘purchasing power parities for gross domestic
product’’ rates as published by the Organisation
for Economic Co-operation and Development
(OECD) in 2011 (UK: 1 USD = 0.6997 GBP;
Germany: 1 USD = 0.7842 €; France: 1























$1295 $64 (£45) $68 (€53) $116 (€98)
a 2011 for the USA, the UK, and Germany; 2012 for France
b Includes face-to-face consultations and phone consultations
c Percentage calculated on the portion of the population with a linkage with HES inpatient data (i.e., 60.4% of patients in
2011)
d Percentage calculated on the portion of the population with observational data on hospitalizations (i.e., 943 patients in
2012)
e All costs expressed in 2011 USD; currencies were converted using ‘‘purchasing power parities on GDP’’ as published by
OECD
f All costs for France were calculated on the portion of the population with observational data on hospitalizations (i.e., 943
patients in 2012)
HRU health resource utilization, GP/PCP general practitioner/primary care practitioner, SD standard deviation, ED
emergency department, GDP gross domestic product, OECD organisation for economic co-operation and development,
HES hospital episode statistics
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Analytical Approach
Data were analyzed using SAS software version 9
(SAS Institute, Cary, NC, USA). Chi-square tests
were conducted to compare the distribution of
categorical variables, while the Wilcoxon rank
sum test was used for continuous variables.
Multivariate models were fit separately in each
country and for each outcome to identify, in
the first post-index panel-year: the drivers of
disease control status, number of
gout-attributed and non-gout-attributed GP/
PCP visits, number of non-gout-attributed
hospitalizations, and total gout-attributed
costs in the second post-index panel-year. To
determine predictors of disease control, a
logistic regression model was constructed. To
determine the drivers of resource utilization,
Poisson regression models were fit as the
dependent variables were discrete counts of
events. For drivers of gout-attributed cost, a
generalized linear model using gamma
distribution with log-link function was fit to
adjust for the skew typically found in cost data.
In all multivariate models, the dependent
variable was modeled as a function of the
same set of demographic (age class, sex),
treatment (chronic ULT-treated, treated for
\60 days, untreated, and adherence to ULT in
the first post-index panel), and clinical
characteristics (Charlson Comorbidity Index
[CCI] and control status in first preindex
panel). Regression coefficients (or their
transformation, e.g., odds ratios with 95%
confidence intervals [CI]) and associated
P values are reported. A P value \0.05 was
considered statistically significant.
Compliance with Ethics Guidelines
This article is based primarily on previously and
routinely collected data in the databases used
for the study, in compliance with the rules for
each database. The UK part of this study was
approved by the Independent Scientific
Advisory Committee for MHRA database
research (ISAC) under protocol number
13_134, as required for use of CPRD data.
Some complementary retrospective data were
collected in France from a sample of GPs
participating in the French Disease Analyzer
database, with approval obtained from the
‘‘CNIL’’ (‘‘Commission Nationale de
l’Informatique et des Liberte´s’’, ref: MMS/MKE/
AR/144351). Beyond this, the current report
does not involve any new studies of human or




The total number of gout patients fulfilling the
main eligibility criteria for HRU and
cost-descriptive analysis was 105,112 in the
USA, 29,758 in the UK, 49,722 in Germany,
and 13,213 in France (Table 1; Table S2). The
main reason for attrition across the four
countries was non-continuous observation
during follow-up (please see Table S2 in the
supplemental material for details). Within the
overall population, the number of evaluable
patients with sUA laboratory values to assess
control status in the second post-index
panel-year was 2560 (2.4%) in the USA, 4385
(14.7%) in the UK, 20,397 (41.0%) in Germany,
and 967 (7.3%) in France (Table 1). In this
subpopulation, the average (standard deviation)
age at index-date was similar in the UK
(64.0 years [12.8]), Germany (68.9 [11.2]), and
France (68.7 [11.2]) and substantially lower in
the USA (53.6 [9.8]) (Table 1). The percentage of
male patients ranged between 69.7% (Germany)
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and 88.6% (USA). The most frequent
comorbidities recorded in the preindex panel
were essential hypertension and
hyperlipidemia. The total cohorts and the sUA
cohorts were similar across characteristics
(Table 1).
Description of Treatment Patterns
in the First Post-index Panel-Year
A majority of patients in the total eligible
population (i.e., not limited to patients with
evaluable control status) were chronic
ULT-treated during the first post-index
panel-year (USA: 70.9%; UK: 86.3%; Germany:
81.6%), with the exception of France, where the
percentage was 14.3% (Table 1), although the
proportion of patients with some ULT, but not
fulfilling defined criteria for chronic treatment
due to gaps or short treatment, was highest in
France: 32.7% (USA: 10.3%; Germany: 4.2%;
UK: 3.1%). Conversely, the proportion of
entirely untreated patients was 18.8% in the
USA, 10.6% in UK, 13.9% in Germany, and
53.0% in France.
Among treated patients, most received only
one ULT during the panel-year (USA: 83.3%;
UK: 99.7%; Germany: 99.4%; France: 99.8%),
with allopurinol the most commonly
administered (USA: 89.5%; UK: 99.3%;
Germany: 97.6%; France: 90.8%). The average
daily allopurinol dose was 240.0 mg in the USA,
238.9 mg in UK, 253.8 in Germany, and
186.6 mg in France. A low percentage of
patients received an average daily allopurinol
dose[300 mg (USA: 1.4%; UK: 4.4%; Germany:
0.5%; France: 0.4%). Febuxostat was the second
most commonly prescribed ULT in the USA
(9.5%) and France (9.2%), but was seldom
prescribed in the UK (0.2%) and Germany
(0.4%). Other ULTs included sulfinpyrazone in
the UK (0.7%) and probenecid or fixed
allopurinol/benzbromarone combinations in
Germany (both 1.3%). Treatment adherence to
any ULT, measured in treated patients over the
course of the whole panel, was 63.9% in the
USA, 84.3% in UK, 69.0% in Germany, and
24.8% in France.
Rate of Uncontrolled Gout in the Second
Post-index Panel-Year
Within the population with evaluable control
status in the second post-index panel-year, the
proportion of patients with uncontrolled gout
was 62.9% in the USA (controlled: 32.7%;
undefined: 4.4%), 55.8% in UK (41.7; 2.5%),
62.0% in Germany (36.8; 1.2%), and 31.3% in
France (66.4; 2.3%). The proportion of patients
with evidence of available sUA testing who had
C1 elevated sUA (C6 mg/dl) was 51.5% in the
USA, 32.7% in UK, 42.3% in Germany, and
30.4% in France, the remaining uncontrolled
patients being identified by occurrence of C2
flares. Tophi were documented in \0.1% of
patients across the four countries. The rate of
uncontrolled gout was consistently higher in
patients untreated during the previous panel
than in chronic ULT patients (USA: 77.5% vs.
55.4%; UK: 93.1% vs. 49.7%; Germany: 84.2%
vs. 56.7%; France: 33.2% vs. 32.9%).
Multivariate logistic regression among the
patients with defined control status in the
second post-index panel-year showed that in
the USA, UK, and Germany, the following
characteristics in the first post-index year were
associated with higher probability of being
controlled in the second post-index year:
female gender, chronic ULT-treated, and[80%
adherent to ULT in the previous panel-year, as
well as having fewer comorbidities reflected by
CCI score (Table 2). In the USA and Germany,
the probability of being controlled increased
with age. The model could not be evaluated for
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France, due to the low number of patients with
defined control status, resulting in
non-convergence of the multivariate model
(Table 2).
HRU in the Second Post-index Panel-Year
The proportion of patients in the total eligible
population with C1 non-gout-attributed/gout-
attributed GP/PCP visit, respectively, was 58.8/
28.2% in the USA, 99.2/7.8% in UK, 97.9/0.5%
in Germany, and 96.4/7.0% in France (Table 3).
The proportion of patients with gout-attributed
GP/PCP visits was consistently higher in
uncontrolled than controlled patients (USA:
43.0% vs. 37.3%, P = 0.011; UK: 17.9% vs.
4.6%, P\0.001; Germany: 0.7% vs. 0.2%,
P\0.001; France: 10.4% vs. 5.0%, P = 0.003).
The proportion of patients with C1
non-gout-attributed hospitalization was 10.0%
in the USA, 27.2% in UK (calculated on the
patient subset with linked hospitalization data,
i.e., 60.4% of total eligible population), 12.6%
in Germany, and 10.3% in France (calculated on
the patient subset with additional
hospitalization data; n = 943) (Table 3). About
31.2% of US patients and 4.6% of UK patients
consulted a specialist for a gout-attributed
reason (Table 3).
The multivariate analysis of HRU among the
patients with defined control status in the first
post-index panel-year showed that when
adjusting simultaneously for demographics,
treatment, and clinical characteristics, the
significant predictors most frequently
associated with higher numbers of
non-gout-attributed GP/PCP consultations in
the second post-index panel-year were older
age (USA, UK, Germany), female gender (all
countries), uncontrolled in the previous
panel-year (UK, Germany, France), chronic
ULT-treated in the previous panel-year (UK,
Germany, France), and having higher CCI score
(all countries) (Table 4). Similarly, a higher CCI
score in the previous panel-year was associated
with higher numbers of non-gout-attributed
hospitalizations (USA, UK, Germany). Finally,
more gout-attributed consultations with a GP/
PCP were likely in patients with the following
characteristics: being older (Germany, France),
having a higher CCI score in the previous
panel-year (USA, France), being uncontrolled
in the previous panel-year (USA, UK, Germany,
France), and not being ULT-treated in the
previous panel-year (UK, Germany) (Table 4).
Healthcare Costs in the Second Post-index
Panel-Year
The average all-cause healthcare cost per
patient, expressed as 2011 USD and calculated
over of the whole panel-year, was $13,514 in
the USA, $2620 in UK, $1671 in Germany, and
$1463 in France. Gout-attributed costs were
lower than non-gout-attributed costs in all four
countries (Table 3).
Based on multivariate analysis, patient
characteristics resulting in higher
gout-attributed costs were CCI score in the
previous panel-year (USA, UK, Germany),
being uncontrolled in the previous panel-year
(UK, Germany, France), and being chronic
ULT-treated in the previous panel-year (USA,
Germany) (Table 4).
DISCUSSION
Despite the high rate of ULT in the study
population, [50% of patients with evaluable
control status (i.e., with available sUA
assessments) in all four countries remained
uncontrolled, suggesting inadequacy of gout
management in the real-world setting. The
study also revealed poor compliance to
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treatment guidelines. Average allopurinol doses
were below 300 mg in each country (most
notably in France, at 186.6 mg), despite
guideline recommendations that the dose can
be advanced to 300 mg daily and above for
those without renal impairment, in order to
achieve target sUA in a substantial proportion
of patients. Suboptimal dosing of allopurinol is
recognized to be a common issue in the
management of gout worldwide [13, 34, 35].
In addition, whereas EULAR and ACR guidelines
recommend treating to a target sUA, including
continuing measurements once the sUA target
is achieved (every 6 months), the high
percentage of patients with no sUA data—even
in countries where all laboratory values were
included in the data (Germany, UK)—clearly
indicates that many patients are maintained on
ULT without reassessment of sUA control.
In some cases (Germany, UK, France), lack of
disease control resulted in increased utilization
of healthcare resources (both gout-attributed
and non-gout-attributed) and increased
gout-attributed costs. In addition, it should be
reiterated that the proportion of patients with
gout-attributed GP/PCP visits was consistently
and significantly higher in uncontrolled than
controlled patients across all four countries.
These findings suggest that in patients with
established gout who received ULT treatment,
longer persistence and higher adherence to ULT
were associated with better control; however,
this is only generalizable to the minority of
patients with sUA testing. Overall,
non-gout-attributed healthcare utilization and
costs were higher than gout-attributed
healthcare utilization and costs. This finding
agrees with other studies assessing the economic
burden of gout. Rai et al. [36] identified five
studies reporting all-cause direct costs associated
with gout patients; depending on the
subpopulation studied, the all-cause annual
direct costs ranged from $4733 (employed
patients) to $18,362 (treatment-refractory
patients), while gout-attributed costs ranged
from $172 to $6179 across studies.
The assessment of disease control presented
here must be viewed in light of the limitations
in assessing clinical measures with retrospective
data. First, the definition of controlled gout was
met if there was no sUA elevation ([6 mg/dl),
no diagnosis code for tophus, and no flare
documented, while uncontrolled gout was
defined by C2 flares or sUA elevation. As
described below, in practice, the contribution
of the ‘‘tophus’’ component of the definition of
gout status was minimal, as tophi were
under-documented. Incidences of flares can be
reduced by prophylactic medications as well as
ULT. However, guidelines recommend using
prophylaxis for up to 6 months after initiation
of ULT, while disease control in our study was
assessed following the preindex 12-month
period in established gout patients.
The reliability of gout diagnosis within
databases in general represents a potential
limitation seen for the majority of rheumatic
diagnoses [37]. However, such differences are
likely an artifact of comparing against disease
definitions established to evaluate patients
prospectively in a clinical setting or using
epidemiologic surveys [38]. It is likely that the
rate of uncontrolled disease in the overall
population was underestimated, since
uncontrolled gout was assessed through a
composite endpoint including elevated sUA
measurements, occurrence of flares, and tophi,
each of which is subject to data-related
limitations in estimations. Under-reporting of
tophi, in particular, is relevant, as previous work
has shown that patients use more resources
when tophi are present [39, 40].
For the USA and France, sUA data were
obtained from an external data source for only
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a subset of eligible patients, resulting in
relatively low percentages of patients with
evaluable control status in the second
post-index panel-year (2.4% and 7.3%). In
addition, the group in France on chronic ULT
was very small (102 patients), and the
uncertainty around sUA estimates was high,
reflected in the very wide CI around the
estimated effect of treatment on control status,
odds ratio 1.02 (95% CI 0.06; 17.55) for treated
versus not treated. Even in the UK and
Germany—where all laboratory results were
included in the main database—the low level
of testing did not allow systematic evaluation of
control status. Due to this limitation, all
analyses involving gout control status were
restricted to patients with available sUA data,
and this additional eligibility criterion could
have resulted in overestimation of the rate of
uncontrolled gout in this subpopulation, since
patients with suspected sUA elevation may have
been more likely to be tested. Also, there is no
specific diagnosis code for flares; consequently,
identification of flares was based on an
algorithm requiring a specific outpatient visit
or hospitalization while, in the real world,
many flares might be self-treated and therefore
remain undetected in primary care databases.
The specificities of the various data sources
used for this study should be taken into account
when comparing results across the four
countries. For instance, PharMetrics Plus is a
claims database consisting of commercially
insured working adults; this resulted in a US
study population younger—and with
potentially less severe gout—than in the other
countries. The prevalence of chronic
morbidities (especially hypertension and
diabetes) was relatively low in the UK versus
other published prevalence rates [41] or versus
prevalence rates observed for instance in the
German or US populations; one possible
explanation resides in the specificity of the
British National Health Service, where the GP/
PCP plays a role of gatekeeper. Over the course
of the patient’s affiliation to a practice, the data
are centralized at the GP/PCP office;
consequently, chronic diseases are coded when
they first occur (or at the first visit if the patient
is new to the practice) and are less likely to be
systematically recoded at each new visit, and
may consequently be missed when the look
back period is limited to 1 year. A similar bias
was observed in the French data, and to some
extent probably affects also the German and US
data due to the short look back period. The
varying level of sUA data availability also
resulted in cross-country variation in the
assessment of disease control status.
Several data-related factors may also explain
the high between-countries variability in
estimates of resource utilization and related
costs. In particular, the average number of GP/
PCP consultations reported in the UK was much
higher than in the USA, Germany, and France,
because the CPRD data document all contacts
between the patient and the practice (i.e.,
including phone calls or prescription renewals
handled by a nurse); however, the valorization
of consultations was made taking this into
account and applying distinct unit costs to the
different types of consultation.
The cost estimates, both gout- and
non-gout-attributed, were in a higher range in
the USA, which is because the billing
information related to all healthcare services
was a primary purpose of and directly available
from the claims database, while costs had to be
obtained from external sources in the other
countries. Compared with the USA, the
European databases also lacked some
health-related data, likely contributing to
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underestimation of costs. In France and
Germany, limited information (if any) was
available on visits to specialists.
Hospitalization data were only partially
available in European countries, i.e., indirectly
(from referrals, so only elective hospitalizations
could be captured) in Germany and for a subset
of patients in the UK and France; this resulted in
low hospitalization rates, low counts of
gout-attributed hospitalizations, and low
associated cost estimates. More generally, the
algorithms used to identify gout-attributed
resources were very conservatively defined;
also, they were very sensitive to attribution
issues resulting from possible misclassification.
Finally, even when data allowed for coding of
diagnoses, the diagnosis of gout appeared to be
underreported, as evidenced by the high
number of patients receiving ULT with no
diagnosis of gout documented in the same
record. All this contributed to low counts of
gout-attributed HRUs and possibly
underestimated gout-attributed costs.
CONCLUSION
Despite the limitations, the study provides
important new evidence on large patient
populations in four countries indicating that
current management of gout is consistently
suboptimal in terms of sUA monitoring and
treatment options. As a consequence, an
important proportion of patients remain
uncontrolled, even while treated with
high-dose ULT, resulting not only in the
symptomatic sequelae of continued flares and
tophi, but also in continued subclinical urate
crystal deposition. Additional effective and
convenient treatment options are needed for
these patients to improve disease control and
minimize healthcare utilization and costs.
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